CNS

2017 Report: Trends in CNS Dealmaking, 2012-16 – Research and Markets

DUBLIN–(BUSINESS WIRE)–The “Trends in CNS Dealmaking, 2012-16” report has been added to Research and Markets’ offering.

Diseases of the central nervous system (CNS) offer considerable opportunity to drug developers and marketers. A few CNS markets, such as multiple sclerosis, are already highly competitive, whereas others including potential blockbuster areas like Alzheimer’s disease offer a kind of therapeutic whitespace where few if any drugs are approved, and the medical need is dire. Regardless of the level of competition in a specific therapeutic area, there remains significant unmet medical need in virtually all CNS disease areas. Drug discovery and development have proven exceptionally difficult in this space, but better disease categorization and diagnosis – through the use of genetic markers or imaging technology, for example – may improve success for CNS drug developers.

The field has proven so challenging in the past that many larger companies exited CNS drug development. Companies that have remained active in CNS and others that are rejoining the fray argue that…